Literature DB >> 21681554

Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.

Daniel Mucs1, Richard A Bryce, Pascal Bonnet.   

Abstract

The identification of new, potent and selective inhibitors of important protein kinase targets is a major goal of drug discovery. Here we analyze the crystal structures of 55 protein kinase complexes with Type II inhibitors and find they adopt a conserved twisted V-shape, with an angle of 121 ± 8° and twist of 78 ± 8°. The tightly conserved twist appears important in ensuring ligands curve around the protein backbone and towards the deep pocket. From this, we develop predictive pharmacophore- and shape-based screens to identify Type II inhibitors from a database which also contains Type I inhibitors as decoys. Both approaches exhibit a good level of discrimination for Type II molecules. The most effective pharmacophore model requires six features and three excluded volume regions. Shape-based screening using ROCS generally performs at least as well as pharmacophore approaches. There is only a moderate dependence of shape-based or pharmacophore-based screens on the underlying conformer generator (MOE, Macromodel, Omega and SPE), as well as on ligand linkage chemistry (amide and urea). Finally, we apply our approach to retrieval of Type II inhibitors from a modified version of the DUD database, containing over 104,000 compounds. We observe good enrichment, providing further evidence that the in silico screens developed here will constitute useful guides for identification of small molecule inhibitors targetting protein kinases in their inactive conformational state.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681554     DOI: 10.1007/s10822-011-9442-0

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  39 in total

Review 1.  Structural biology in drug design: selective protein kinase inhibitors.

Authors:  Giovanna Scapin
Journal:  Drug Discov Today       Date:  2002-06-01       Impact factor: 7.851

2.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Authors:  Brian L Hodous; Stephanie D Geuns-Meyer; Paul E Hughes; Brian K Albrecht; Steve Bellon; James Bready; Sean Caenepeel; Victor J Cee; Stuart C Chaffee; Angela Coxon; Maurice Emery; Jenne Fretland; Paul Gallant; Yan Gu; Doug Hoffman; Rebecca E Johnson; Richard Kendall; Joseph L Kim; Alexander M Long; Michael Morrison; Philip R Olivieri; Vinod F Patel; Anthony Polverino; Paul Rose; Paul Tempest; Ling Wang; Douglas A Whittington; Huilin Zhao
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

3.  Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.

Authors:  Matthäus Getlik; Christian Grütter; Jeffrey R Simard; Sabine Klüter; Matthias Rabiller; Haridas B Rode; Armin Robubi; Daniel Rauh
Journal:  J Med Chem       Date:  2009-07-09       Impact factor: 7.446

4.  How to optimize shape-based virtual screening: choosing the right query and including chemical information.

Authors:  Johannes Kirchmair; Simona Distinto; Patrick Markt; Daniela Schuster; Gudrun M Spitzer; Klaus R Liedl; Gerhard Wolber
Journal:  J Chem Inf Model       Date:  2009-03       Impact factor: 4.956

5.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.

Authors:  Jeffrey R Simard; Matthäus Getlik; Christian Grütter; Vijaykumar Pawar; Sabine Wulfert; Matthias Rabiller; Daniel Rauh
Journal:  J Am Chem Soc       Date:  2009-09-23       Impact factor: 15.419

6.  Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches.

Authors:  Johannes Kirchmair; Stojanka Ristic; Kathrin Eder; Patrick Markt; Gerhard Wolber; Christian Laggner; Thierry Langer
Journal:  J Chem Inf Model       Date:  2007-10-11       Impact factor: 4.956

7.  Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition.

Authors:  Ac Backes; B Zech; B Felber; B Klebl; G Müller
Journal:  Expert Opin Drug Discov       Date:  2008-12       Impact factor: 6.098

8.  N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.

Authors:  Holly L Deak; John R Newcomb; Joseph J Nunes; Christina Boucher; Alan C Cheng; Erin F DiMauro; Linda F Epstein; Paul Gallant; Brian L Hodous; Xin Huang; Josie H Lee; Vinod F Patel; Stephen Schneider; Susan M Turci; Xiaotian Zhu
Journal:  Bioorg Med Chem Lett       Date:  2007-12-05       Impact factor: 2.823

9.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  2 in total

1.  Conformational landscape and low lying excited states of imatinib.

Authors:  Emil Vinţeler; Nicoleta-Florina Stan; Raluca Luchian; Călin Căinap; João P Prates Ramalho; Vasile Chiş
Journal:  J Mol Model       Date:  2015-03-13       Impact factor: 1.810

2.  PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.

Authors:  Fabrice Carles; Stéphane Bourg; Christophe Meyer; Pascal Bonnet
Journal:  Molecules       Date:  2018-04-15       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.